Immunic, Inc. Stock Analysis & AI Score
Immunic, Inc. (IMUX) has an ST Score of 46.5 (C+), driven by its Growth (A+) and held back by its Profitability (D-). Analysts rate it Buy with a $22.13 price target (+137.4% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Immunic, Inc. (IMUX) has an ST Score of 46.5 (C+), driven by its Growth (A+) and held back by its Profitability (D-). Analysts rate it Buy with a $22.13 price target (+137.4% upside).
- Strongest
- GrowthA+
- Weakest
- ProfitabilityD-
All factor grades
- GrowthA+
- ForecastB+
- ValuationB-
- Financial StrengthB-
- MomentumD+
- ProfitabilityD-
- Piotroski2/9
Contact
IMUX stock: frequently asked questions
What is IMUX's ST Score?
Immunic, Inc. (IMUX) has an ST Score of 46.5 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is IMUX a buy, hold, or sell?
Analysts rate IMUX a Buy, with a price target of $22.13 (+137.4% vs the current price). Our ST Score grades it C+ (46.5/100). The ST Score is a data-driven signal, not a recommendation.
What are IMUX's factor grades?
Valuation B-, Profitability D-, Financial Strength B-, Momentum D+, Growth A+, Forecast B+.
What is IMUX's valuation grade?
Immunic, Inc. (IMUX) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is IMUX's growth grade?
Immunic, Inc. (IMUX) earns a growth grade of A+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is IMUX's profitability grade?
Immunic, Inc. (IMUX) earns a profitability grade of D-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is IMUX's financial strength grade?
Immunic, Inc. (IMUX) earns a financial strength grade of B-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for IMUX?
The average analyst price target for Immunic, Inc. (IMUX) is $22.13 from 12 analysts, which is +137.4% versus the recent price of $9.32.
What is IMUX's Piotroski score?
Immunic, Inc. (IMUX) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.